|
|
 |
|
Viewing report
|
|
|
|
CeNeRx BioPharma, Inc. - Product Pipeline Review - H2 2011
Global Markets Direct, Sep 2011, Pages: 46
CeNeRx BioPharma, Inc. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “CeNeRx BioPharma, Inc. – Product Pipeline Review – H2 2011” provides data on the CeNeRx BioPharma, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, CeNeRx BioPharma, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from CeNeRx BioPharma, Inc. and industry–specific third party sources, put together by Global Markets Direct’s team.
Scope
- CeNeRx BioPharma, Inc. - Brief CeNeRx BioPharma, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CeNeRx BioPharma, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CeNeRx BioPharma, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CeNeRx BioPharma, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate CeNeRx BioPharma, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CeNeRx BioPharma, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CeNeRx BioPharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CeNeRx BioPharma, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CeNeRx BioPharma, Inc. and identify potential opportunities in those areas.
|
|
|
|
